Back to Search
Start Over
Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial
- Source :
- The Journal of Infectious Diseases
- Publication Year :
- 2019
- Publisher :
- Oxford University Press (OUP), 2019.
-
Abstract
- Background Respiratory syncytial virus (RSV) is a common cause of respiratory tract illness and hospitalization in neonates and infants. RSV vaccination during pregnancy may protect offspring in their first months of life. Methods This randomized, observer-blind, multicenter, phase 2 study evaluated the immunogenicity and safety of an RSV candidate vaccine in healthy nonpregnant women aged 18–45 years. Four hundred participants were randomized (1:1:1:1) to receive a single intramuscular dose of vaccine containing 30 µg, 60 µg, or 120 µg of RSV fusion protein engineered to preferentially maintain a prefusion conformation (RSV-PreF vaccine) or placebo. Results Thirty days postvaccination, RSV-A neutralizing antibody geometric mean titers (GMTs) increased 3.75-, 4.42- and 4.36-fold; RSV-B neutralizing antibody GMTs 2.36-, 2.54- and 2.76-fold; and palivizumab competing antibody (PCA) concentrations 11.69-, 14.38- and 14.24-fold compared with baseline levels in the 30 µg, 60 µg, and 120 µg RSV-PreF groups, respectively. Antibody titers and PCA concentrations at day 30 were significantly higher with the 120 µg compared to the 30 µg RSV-PreF vaccine. All RSV-PreF vaccine formulations and the placebo had similar reactogenicity profiles. No serious adverse events were considered to be related to the RSV-PreF vaccine. Conclusions The 3 formulations of the investigational RSV-PreF vaccine were well-tolerated and induced RSV-A and RSV-B neutralizing antibodies and PCAs in healthy, nonpregnant women. Clinical Trials Registration NCT02956837.<br />Three formulations of an investigational maternal respiratory syncytial virus (RSV) vaccine containing 30, 60, or 120 µg of antigen were well-tolerated and elicited a rise in RSV-A and RSV-B neutralizing antibody titers as well as palivizumab-competing antibody titers in healthy nonpregnant women.
- Subjects :
- safety
Adult
Palivizumab
Adolescent
Drug-Related Side Effects and Adverse Reactions
nonpregnant women
viruses
respiratory syncytial virus
Respiratory Syncytial Virus Infections
Antibodies, Viral
Placebo
Injections, Intramuscular
Placebos
Major Articles and Brief Reports
Young Adult
randomized trial
Respiratory Syncytial Virus Vaccines
Humans
Immunology and Allergy
Medicine
neutralizing antibodies
Adverse effect
Neutralizing antibody
Vaccines
Vaccines, Synthetic
Reactogenicity
biology
business.industry
Immunogenicity
Antibody titer
virus diseases
respiratory system
Middle Aged
palivizumab competing antibody
Antibodies, Neutralizing
Healthy Volunteers
Vaccination
Infectious Diseases
Vaccines, Subunit
Immunology
biology.protein
Female
maternal immunization
business
Viral Fusion Proteins
medicine.drug
Subjects
Details
- ISSN :
- 15376613, 00221899, and 02956837
- Volume :
- 220
- Database :
- OpenAIRE
- Journal :
- The Journal of Infectious Diseases
- Accession number :
- edsair.doi.dedup.....a645ed9cf7dd59f52dd07023b5aeae66